Cargando…

Comprehensive Characterization of Transforming Growth Factor Beta Receptor 1 in Stomach Adenocarcinoma Identifies a Prognostic Signature for Predicting Clinical Outcomes and Immune Infiltrates

BACKGROUND: Stomach adenocarcinoma (STAD) ranks as the third leading cause of cancer death worldwide. TGF‑β receptor 1 (TGFBR1), serving important roles in the TGF‑β family, the mechanisms whereby TGFBR1 governs tumor progression, immune cell infiltration in STAD remains unintelligible. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yi, Zhang, Haiyang, Zhang, Yan, Wang, Peiyun, Zhu, Kegan, Ba, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965104/
https://www.ncbi.nlm.nih.gov/pubmed/35368798
http://dx.doi.org/10.2147/IJGM.S353879
_version_ 1784678361041207296
author He, Yi
Zhang, Haiyang
Zhang, Yan
Wang, Peiyun
Zhu, Kegan
Ba, Yi
author_facet He, Yi
Zhang, Haiyang
Zhang, Yan
Wang, Peiyun
Zhu, Kegan
Ba, Yi
author_sort He, Yi
collection PubMed
description BACKGROUND: Stomach adenocarcinoma (STAD) ranks as the third leading cause of cancer death worldwide. TGF‑β receptor 1 (TGFBR1), serving important roles in the TGF‑β family, the mechanisms whereby TGFBR1 governs tumor progression, immune cell infiltration in STAD remains unintelligible. METHODS: We used the TCGA, GEPIA, and HPA databases to explore TGFBR1 expression in STAD, the correlation between TGFBR1 expression and the clinical features. A receiver operating characteristic (ROC) curve and nomogram were constructed, and LASSO (the Least Absolute Shrinkage and Selection Operator)-selected features were used to build the TGFBR1 prognostic signature. GSEA is used to find the potential mechanism of TGFBR1 to promote the malignant process of STAD. We explored the influence of the TGFBR1 on the immune microenvironment of STAD through the TIMER2.0 and GEPIA database. RESULTS: In our study, TGFBR1 expression was significantly elevated in STAD and positively co-expression with pathologic stage, lymph node metastases (LNM) stage and histopathological grade. Nine factors with non-zero coefficients were identified by LASSO-selected features. Survival analysis revealed that patients with high TGFBR1 had shorter OS, FP, and PPS. Multivariate Cox analysis revealed that TGFBR1 was an independent prognostic factor for OS in STAD. The ROC analysis suggested that high diagnostic value with the AUC of TGFBR1 was 0.739. GSEA revealed that high TGFBR1 expression was correlated with pathway in cancer, MAPK signaling pathway, NOTCH signaling pathway, and VEGF-C production. ssGSEA showed that TGFBR1 is correlated with NK cells, Tem and Th17 cells. Furthermore, elevated TGFBR1 expression was found to be significantly correlated with several immune checkpoint and immune markers associated with immune cell subsets. CONCLUSION: In summary, TGFBR1 could be a prognostic biomarker and an important regulator of immune cell infiltration in STAD. The present study revealed the probable underlying molecular mechanisms of TGFBR1 in STAD and provided a potential target for improving the prognosis.
format Online
Article
Text
id pubmed-8965104
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-89651042022-03-31 Comprehensive Characterization of Transforming Growth Factor Beta Receptor 1 in Stomach Adenocarcinoma Identifies a Prognostic Signature for Predicting Clinical Outcomes and Immune Infiltrates He, Yi Zhang, Haiyang Zhang, Yan Wang, Peiyun Zhu, Kegan Ba, Yi Int J Gen Med Original Research BACKGROUND: Stomach adenocarcinoma (STAD) ranks as the third leading cause of cancer death worldwide. TGF‑β receptor 1 (TGFBR1), serving important roles in the TGF‑β family, the mechanisms whereby TGFBR1 governs tumor progression, immune cell infiltration in STAD remains unintelligible. METHODS: We used the TCGA, GEPIA, and HPA databases to explore TGFBR1 expression in STAD, the correlation between TGFBR1 expression and the clinical features. A receiver operating characteristic (ROC) curve and nomogram were constructed, and LASSO (the Least Absolute Shrinkage and Selection Operator)-selected features were used to build the TGFBR1 prognostic signature. GSEA is used to find the potential mechanism of TGFBR1 to promote the malignant process of STAD. We explored the influence of the TGFBR1 on the immune microenvironment of STAD through the TIMER2.0 and GEPIA database. RESULTS: In our study, TGFBR1 expression was significantly elevated in STAD and positively co-expression with pathologic stage, lymph node metastases (LNM) stage and histopathological grade. Nine factors with non-zero coefficients were identified by LASSO-selected features. Survival analysis revealed that patients with high TGFBR1 had shorter OS, FP, and PPS. Multivariate Cox analysis revealed that TGFBR1 was an independent prognostic factor for OS in STAD. The ROC analysis suggested that high diagnostic value with the AUC of TGFBR1 was 0.739. GSEA revealed that high TGFBR1 expression was correlated with pathway in cancer, MAPK signaling pathway, NOTCH signaling pathway, and VEGF-C production. ssGSEA showed that TGFBR1 is correlated with NK cells, Tem and Th17 cells. Furthermore, elevated TGFBR1 expression was found to be significantly correlated with several immune checkpoint and immune markers associated with immune cell subsets. CONCLUSION: In summary, TGFBR1 could be a prognostic biomarker and an important regulator of immune cell infiltration in STAD. The present study revealed the probable underlying molecular mechanisms of TGFBR1 in STAD and provided a potential target for improving the prognosis. Dove 2022-03-25 /pmc/articles/PMC8965104/ /pubmed/35368798 http://dx.doi.org/10.2147/IJGM.S353879 Text en © 2022 He et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
He, Yi
Zhang, Haiyang
Zhang, Yan
Wang, Peiyun
Zhu, Kegan
Ba, Yi
Comprehensive Characterization of Transforming Growth Factor Beta Receptor 1 in Stomach Adenocarcinoma Identifies a Prognostic Signature for Predicting Clinical Outcomes and Immune Infiltrates
title Comprehensive Characterization of Transforming Growth Factor Beta Receptor 1 in Stomach Adenocarcinoma Identifies a Prognostic Signature for Predicting Clinical Outcomes and Immune Infiltrates
title_full Comprehensive Characterization of Transforming Growth Factor Beta Receptor 1 in Stomach Adenocarcinoma Identifies a Prognostic Signature for Predicting Clinical Outcomes and Immune Infiltrates
title_fullStr Comprehensive Characterization of Transforming Growth Factor Beta Receptor 1 in Stomach Adenocarcinoma Identifies a Prognostic Signature for Predicting Clinical Outcomes and Immune Infiltrates
title_full_unstemmed Comprehensive Characterization of Transforming Growth Factor Beta Receptor 1 in Stomach Adenocarcinoma Identifies a Prognostic Signature for Predicting Clinical Outcomes and Immune Infiltrates
title_short Comprehensive Characterization of Transforming Growth Factor Beta Receptor 1 in Stomach Adenocarcinoma Identifies a Prognostic Signature for Predicting Clinical Outcomes and Immune Infiltrates
title_sort comprehensive characterization of transforming growth factor beta receptor 1 in stomach adenocarcinoma identifies a prognostic signature for predicting clinical outcomes and immune infiltrates
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965104/
https://www.ncbi.nlm.nih.gov/pubmed/35368798
http://dx.doi.org/10.2147/IJGM.S353879
work_keys_str_mv AT heyi comprehensivecharacterizationoftransforminggrowthfactorbetareceptor1instomachadenocarcinomaidentifiesaprognosticsignatureforpredictingclinicaloutcomesandimmuneinfiltrates
AT zhanghaiyang comprehensivecharacterizationoftransforminggrowthfactorbetareceptor1instomachadenocarcinomaidentifiesaprognosticsignatureforpredictingclinicaloutcomesandimmuneinfiltrates
AT zhangyan comprehensivecharacterizationoftransforminggrowthfactorbetareceptor1instomachadenocarcinomaidentifiesaprognosticsignatureforpredictingclinicaloutcomesandimmuneinfiltrates
AT wangpeiyun comprehensivecharacterizationoftransforminggrowthfactorbetareceptor1instomachadenocarcinomaidentifiesaprognosticsignatureforpredictingclinicaloutcomesandimmuneinfiltrates
AT zhukegan comprehensivecharacterizationoftransforminggrowthfactorbetareceptor1instomachadenocarcinomaidentifiesaprognosticsignatureforpredictingclinicaloutcomesandimmuneinfiltrates
AT bayi comprehensivecharacterizationoftransforminggrowthfactorbetareceptor1instomachadenocarcinomaidentifiesaprognosticsignatureforpredictingclinicaloutcomesandimmuneinfiltrates